Company intelligence / Profile preview

StemGen

Milano, Lombardia, Italystemgen.net ↗

Ownership: Private
Development stage: Phase 1

Overview

A clinical-stage biotech developing differentiation therapies targeting cancer stem cells. Focused on glioblastoma treatment through cellular reprogramming. Subsidiary Stemgen Biotherapeutics develops skin regeneration products using cell/tissue-based technologies.

Therapeutic areas: OncologyDermatology
Modalities: Differentiation biotherapies(BMP4-based approach mentioned in pipeline)
Industry: Biotech

Drug pipeline

1 asset

hrBMP4

Phase 1

Indications: Glioma, Glioblastoma

Partnerships

University of Bicocca - Milan (lab location)[3]Mention of licensing strategy for GBM therapies[3]

Beyond the preview

Go deeper on StemGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemGen.

Explore the full profile